The relation between hypocholesterolemia and degree of maturation in acute myeloid leukemia.

Abstract:

:Plasma cholesterol concentrations were determined in 83 acute myeloid leukemia patients. Mean plasma cholesterol concentration (+/- S.D.) at the time of diagnosis was 2.91 mmol/L (+/- 1.13). The percentage of AML patients having hypocholesterolemia was 90.4 per cent. The lowest cholesterol levels were observed in the poorly differentiated FAB subtypes of acute myeloid leukaemia: AMyL(M1) and AMoL(M5a). The results showed that the initial hypocholesterolemia in acute myeloid leukemia is significantly related to the degree of both cytological and cytochemical maturation of leukemic blast cells at diagnosis. The degree of maturation at diagnosis has been shown to be related to prognosis in favour of more differentiated subtypes of acute myeloid leukemia. Also, hypocholesterolemia has been shown in several epidemiological studies to be related to an increased mortality from human cancer. Therefore, the degree of maturation may serve as a link between hypocholesterolemia and the increased mortality from human cancer.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Zyada LE,Hassan HT,Rees JK,Ragab MH

doi

10.1002/hon.2900080109

subject

Has Abstract

pub_date

1990-01-01 00:00:00

pages

65-9

issue

1

eissn

0278-0232

issn

1099-1069

journal_volume

8

pub_type

杂志文章
  • Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.

    abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1002/hon.2152

    authors: Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

    更新日期:2015-09-01 00:00:00

  • Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.

    abstract::Bendamustine and rituximab (BR) are widely used in patients with follicular lymphoma (FL) previously treated with conventional immunochemotherapy, but the role of consolidation radioimmunotherapy in these patients is unknown. This study evaluated the efficacy and safety of consolidation with 90 Yttrium-ibritumomab tiu...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2809

    authors: Miura K,Tsujimura H,Masaki Y,Iino M,Takizawa J,Maeda Y,Yamamoto K,Tamura S,Yoshida A,Yagi H,Yoshida I,Kitazume K,Masunari T,Choi I,Kakinoki Y,Suzuki R,Yoshino T,Nakamura S,Hatta Y,Yoshida T,Kanno M

    更新日期:2020-09-25 00:00:00

  • Epidemiology of multiple myeloma in parts of England, 1984-1993.

    abstract::This paper presents a new analysis of aspects of the descriptive epidemiology of multiple myeloma (MM) for parts of the U.K., 1984-1993. It provides no indication for geographical heterogeneity, nor is there evidence of a decline in rates over the decade. There is, however, evidence that cancer registration inflates M...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199903)17:1<31::aid-hon636

    authors: Cartwright RA,Gilman EA,Nicholson P,Allon D

    更新日期:1999-03-01 00:00:00

  • Comparison of 60 and 80 mg/m2 of daunorubicin in induction therapy of acute myeloid leukaemia.

    abstract::For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2236

    authors: Vaezi M,Bahar B,Mousavi A,Yaghmai M,Kasaeian A,Souri M,Jahani M,Alimoghaddam K,Ghavamzadeh A

    更新日期:2017-03-01 00:00:00

  • Relationship between myeloblasts and cluster-forming cells in acute non-lymphocytic leukemia.

    abstract::The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900020210

    authors: Gustavsson A,Olofsson T,Olsson I

    更新日期:1984-04-01 00:00:00

  • A simple, non-invasive method of assessing the acute hemodynamic effects of doxorubicin.

    abstract::Left ventricular stroke distance was measured by Doppler ultrasound in 10 doxorubicin-treated and 10 control patients. Measurements were made 10 min, 2 h and 4 h after drug administration. Stroke distance (a linear analogue of stroke volume) increased significantly from 12.6 cm (S.D. 2.7) before and 12.5 cm (S.D. 2.7)...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900090107

    authors: Clive S,Dawson A,Bennett B,Rawles J

    更新日期:1991-01-01 00:00:00

  • Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art.

    abstract::The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2676

    authors: Albano D,Bruno A,Patti C,Micci G,Midiri M,Tarella C,Galia M

    更新日期:2020-02-01 00:00:00

  • Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level.

    abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120104

    authors: Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

    更新日期:1994-01-01 00:00:00

  • Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

    abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2378

    authors: Sorigue M,Mercadal S,Alonso S,Fernández-Álvarez R,García O,Moreno M,Pomares H,Alcoceba M,González-García E,Motlló C,González-Barca E,Martin A,Sureda A,Caballero D,Ribera JM,Sancho JM

    更新日期:2017-12-01 00:00:00

  • The burden of autoimmunity in myelodysplastic syndromes.

    abstract::The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present rev...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2423

    authors: Fozza C

    更新日期:2018-02-01 00:00:00

  • ABCG2 (BCRP) expression in normal and malignant hematopoietic cells.

    abstract::ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.714

    authors: Abbott BL

    更新日期:2003-09-01 00:00:00

  • Malignant lymphomas of follicular centre cell origin in man. VII. Prognostic features in small cleaved cell lymphoma.

    abstract::To extend the clinical-pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage II...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070506

    authors: Stein RS,Greer JP,Cousar JB,Hendey GW,Wehner JH,Flexner JM,Collins RD

    更新日期:1989-09-01 00:00:00

  • CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.

    abstract::From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(199809)16:3<117::aid-hon63

    authors: Chim CS,Kwong YL,Lie AK,Lee CK,Liang R

    更新日期:1998-09-01 00:00:00

  • Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.

    abstract::Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070605

    authors: Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

    更新日期:1989-11-01 00:00:00

  • The value of EUS in combination with cytological, flow cytometry, and gene rearrangement in the diagnosis of gastrointestinal lymphoma.

    abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2298

    authors: Yu L,Chen K,Xu Y,Wang S,Liu Q,Ye Q,Ye T,Sun Y

    更新日期:2017-09-01 00:00:00

  • Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation.

    abstract::Reactivation of remote hepatitis B infection (RHBI) is an important cause of morbidity in hematopoietic cell transplant (HCT) patients. We analyzed the prevalence of RHBI in 205 patients who underwent HCT in our centre, serological events related to hepatitis B virus (HBV) reactivation and role of lamivudine prophylax...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2195

    authors: Gupta A,Punatar S,Gawande J,Bagal B,Mathew L,Bhat V,Kannan S,Khattry N

    更新日期:2016-09-01 00:00:00

  • Hematological malignancies in the island of Sardinia, 1974-1993: age and sex distributions and temporal changes in incidence.

    abstract::We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.733

    authors: Broccia G,Deplano W,Dessalvi P,Giannico B,Luxi G,Chessa E,Murru A

    更新日期:2004-09-01 00:00:00

  • A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT

    abstract::The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2786

    authors: Heibl S,Buxhofer-Ausch V,Schmidt S,Webersinke G,Lion T,Piringer G,Kuehr T,Wolf D,Melchardt T,Greil R,Thaler J

    更新日期:2020-12-01 00:00:00

  • Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests.

    abstract::Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a tw...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/1099-1069(200009)18:3<111::aid-hon657>3.0.

    authors: Davies FE,Rawstron AC,Pratt G,Coupe R,Clarke D,Lubenko A,Short K,Perren TJ,Selby PJ,Maclennan S,Major K,Woodhead V,Robinson F,Child JA,Smith GM,Johnson PW,Morgan GJ

    更新日期:2000-09-01 00:00:00

  • Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentin

    abstract::Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2729

    authors: Schütz NP,Ochoa P,Duarte P,Remaggi G,Yantorno S,Corzo A,Zabaljauregui S,Shanley C,Lopresti S,Orlando S,Verri V,Quiroga L,García CA,Fernández V,Fantl D

    更新日期:2020-08-01 00:00:00

  • Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.

    abstract::Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.991

    authors: Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

    更新日期:2011-12-01 00:00:00

  • Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

    abstract::There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2635

    authors: Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

    更新日期:2019-08-01 00:00:00

  • Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.

    abstract::Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2500

    authors: Rothenbühler C,Held U,Manz MG,Schanz U,Gerber B

    更新日期:2018-04-01 00:00:00

  • Cytotoxic and DNA-inhibitory effects of iron chelators on human leukaemic cell lines.

    abstract::Cytotoxic and DNA synthesis inhibitory effects of several iron chelators with different physicochemical properties have been tested in four myeloid leukaemic cell lines (U937, K562, ML2 and HL60). The small lipophilic chelators 8-hydroxyquinoline, tropolone and omadine at 2 X 10(-5) M, caused substantial inhibition of...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900040303

    authors: Kontoghiorghes GJ,Piga A,Hoffbrand AV

    更新日期:1986-07-01 00:00:00

  • In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions.

    abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2724

    authors: Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

    更新日期:2020-10-01 00:00:00

  • Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.

    abstract::Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2427

    authors: Akahoshi Y,Kimura SI,Gomyo A,Hayakawa J,Tamaki M,Harada N,Kusuda M,Kameda K,Ugai T,Wada H,Ishihara Y,Kawamura K,Sakamoto K,Sato M,Terasako-Saito K,Kikuchi M,Nakasone H,Kako S,Kanda Y

    更新日期:2018-02-01 00:00:00

  • Influence of ethnicity and improved outcome of acute myeloid leukaemia: two decades of follow-up of Israeli patient cohort.

    abstract::Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2092

    authors: Goldschmidt N,Cohen SB,Gatt ME,Safrai M,Rund D

    更新日期:2014-06-01 00:00:00

  • COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma.

    abstract::One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900110106

    authors: Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho F

    更新日期:1993-01-01 00:00:00

  • Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

    abstract::This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2515

    authors: Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

    更新日期:2018-10-01 00:00:00

  • Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in Hodgkin's disease.

    abstract::Fourteen patients with Hodgkin's disease (two previously untreated, 12 following relapse or with refractory disease) were treated with a combination chemotherapy regimen comprising chlorambucil, vinblastine, procarbazine, prednisolone, etoposide, vincristine and adriamycin administered on days 1-8. Recombinant human g...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900090608

    authors: Oza AM,Leahy M,Dorey E,Davis CL,Amess J,Horton M,Rohatiner AZ,Wrigley PF,Lister TA

    更新日期:1991-11-01 00:00:00